License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A phase III randomised double-blind placebo-controlled parallel group efficacy and safety study of BI 10773 10 mg 25 mg administered orally once daily over 24 weeks in patients with type 2 diabetes with insufficient glycaemic control despite...

The objective of the current study is to investigate the efficacy safety and tolerability of BI 10773 10 mg 25 mg once daily compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with T2DM with insufficient glycaemic control

FieldValue
Modified
2019-06-15
Release Date
2019-05-08
Identifier
04bd27e0-241d-407c-80dc-2d590342bb6f
License
License Not Specified
Public Access Level
Public